Pharma BD Deal Intelligence
Pharmaceutical Technology characterized the deal as Baxter BioScience's principal oncology entry point, citing $100M in current Oncaspar sales and a clear…
Baxalta closed the acquisition on July 23, 2015 — its first major transaction as an independent company — emphasizing global expansion and broader patient…
Contract Pharma noted the close as Baxalta's debut oncology footprint, with Oncaspar an established standard-of-care biologic and calaspargase pegol the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Baxter BioScience (which spun off as Baxalta in July 2015) acquired the Oncaspar portfolio from Sigma-Tau for approximately $900M, including Oncaspar (pegaspargase), the investigational biologic calaspargase pegol, and global commercial resources. Closed July 23, 2015.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Baxalta Inc. / Sigma-Tau Finanziaria S.p.A. (Oncaspar portfolio) (this deal) | 2015 | $900M | 63 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2015 deals · Hematology deals